CD8A and neoplasm: Notably, preclinical research showed that the antitumor activity of lenvatinib will improve when combined with ICIs by reducing tumor-associated macrophages (TAMs) and increasing the percentage of activated CD8+ T cells secreting interferon (IFN)-γ+ and granzyme B (GzmB) (23).